Brian A Bergmark1,2, Christopher P Cannon2,3, William B White4, Petr Jarolim5, Yuyin Liu3, Marc P Bonaca1, Faiez Zannad6, David A Morrow1,2. 1. TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 3. Baim Institute, Harvard Medical School, Boston, Massachusetts. 4. Pat and Jim Calhoun Cardiology Center, University of Connecticut, Farmington, Connecticut. 5. Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 6. Centre d'Investigation Clinique Inserm 1433 and U 1116, Universite de Lorraine and CHRU, Nancy, France.
Abstract
AIM: To investigate adiponectin levels and cardiovascular (CV) outcomes in patients with diabetes and recent acute coronary syndrome (ACS). MATERIALS AND METHODS: We analysed baseline adiponectin concentration and CV outcomes in 5213 patients with type 2 diabetes enrolled in the EXAMINE trial of alogliptin vs placebo 15 to 90 days (median 45 days) after ACS. Event rates at 18 months are reported. RESULTS: The median (interquartile range) baseline adiponectin concentration was 5.2 (3.5-7.9) μg/mL. Patients with the highest baseline adiponectin concentration (quartile [Q]4) were at significantly higher risk of death from a CV event (8.4% vs 1.7%; P < .0001), hospitalization for heart failure (HF; 7.5% vs 1.7%; P < .0001), and all-cause mortality (10.8% vs 2.4%; P < .0001) compared with those in Q1. After adjusting for age, sex, index event, HF, estimated glomerular filtration rate and hypertension, adiponectin concentration in Q4 remained associated with an increased risk of death from CV causes (hazard ratio [HR] 2.43, 95% confidence interval [CI] 1.52, 3.88), all-cause mortality (HR 2.45, 95% CI 1.65, 3.64), and HF (HR 2.44, 95% CI 1.47, 4.05), without change after stratification by body mass index. There was no significant difference in the rate of myocardial infarction or stroke. CONCLUSIONS: In this contemporary population of patients with diabetes and ACS, adiponectin concentration was independently associated with increased risk of death from CV causes, all-cause mortality, and hospitalization for HF. The relationship between adiponectin and CV outcomes is complex and deserves further study.
RCT Entities:
AIM: To investigate adiponectin levels and cardiovascular (CV) outcomes in patients with diabetes and recent acute coronary syndrome (ACS). MATERIALS AND METHODS: We analysed baseline adiponectin concentration and CV outcomes in 5213 patients with type 2 diabetes enrolled in the EXAMINE trial of alogliptin vs placebo 15 to 90 days (median 45 days) after ACS. Event rates at 18 months are reported. RESULTS: The median (interquartile range) baseline adiponectin concentration was 5.2 (3.5-7.9) μg/mL. Patients with the highest baseline adiponectin concentration (quartile [Q]4) were at significantly higher risk of death from a CV event (8.4% vs 1.7%; P < .0001), hospitalization for heart failure (HF; 7.5% vs 1.7%; P < .0001), and all-cause mortality (10.8% vs 2.4%; P < .0001) compared with those in Q1. After adjusting for age, sex, index event, HF, estimated glomerular filtration rate and hypertension, adiponectin concentration in Q4 remained associated with an increased risk of death from CV causes (hazard ratio [HR] 2.43, 95% confidence interval [CI] 1.52, 3.88), all-cause mortality (HR 2.45, 95% CI 1.65, 3.64), and HF (HR 2.44, 95% CI 1.47, 4.05), without change after stratification by body mass index. There was no significant difference in the rate of myocardial infarction or stroke. CONCLUSIONS: In this contemporary population of patients with diabetes and ACS, adiponectin concentration was independently associated with increased risk of death from CV causes, all-cause mortality, and hospitalization for HF. The relationship between adiponectin and CV outcomes is complex and deserves further study.
Authors: William B White; George L Bakris; Richard M Bergenstal; Christopher P Cannon; William C Cushman; Penny Fleck; Simon Heller; Cyrus Mehta; Steven E Nissen; Alfonso Perez; Craig Wilson; Faiez Zannad Journal: Am Heart J Date: 2011-09-14 Impact factor: 4.749
Authors: Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa Journal: Heart Date: 2004-05 Impact factor: 5.994
Authors: Poghni A Peri-Okonny; Colby Ayers; Naim Maalouf; Sandeep R Das; James A de Lemos; Jarett D Berry; Aslan T Turer; Ian J Neeland; Philipp E Scherer; Wanpen Vongpatanasin Journal: Diabetes Metab Res Rev Date: 2016-08-18 Impact factor: 4.876
Authors: Abhinav Sharma; Muthiah Vaduganathan; João Pedro Ferreira; Yuyin Liu; George L Bakris; Christopher P Cannon; William B White; Faiez Zannad Journal: J Am Heart Assoc Date: 2020-01-04 Impact factor: 5.501